This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
2Q3A Overzicht aandelen
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 0/6 |
| Dividenden | 0/6 |
9 Meters Biopharma, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.24 |
| 52 Week Hoogtepunt | US$6.40 |
| 52 Week Laag | US$0.24 |
| Bèta | 1.48 |
| 11 maand verandering | -62.84% |
| 3 maanden verandering | -81.24% |
| 1 Jaar Verandering | -94.67% |
| 33 jaar verandering | -97.41% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -97.83% |
Recent nieuws en updates
Recent updates
Rendement voor aandeelhouders
| 2Q3A | DE Pharmaceuticals | DE Markt | |
|---|---|---|---|
| 7D | -60.0% | 3.7% | 1.1% |
| 1Y | -94.7% | -7.6% | 18.9% |
Rendement versus industrie: 2Q3A underperformed the German Pharmaceuticals industry which returned -10% over the past year.
Rendement versus markt: 2Q3A underperformed the German Market which returned 8.6% over the past year.
Prijsvolatiliteit
| 2Q3A volatility | |
|---|---|
| 2Q3A Average Weekly Movement | 19.9% |
| Pharmaceuticals Industry Average Movement | 8.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stabiele aandelenkoers: 2Q3A's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: 2Q3A's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| n/a | 10 | Bethany Sensenig | www.9meters.com |
9 Meters Biopharma, Inc. Samenvatting
| 2Q3A fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €8.01m |
| Inkomsten(TTM) | -€41.24m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-0.1x
Koers/WinstverhoudingIs 2Q3A overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| 2Q3A resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$0 |
| Overige uitgaven | US$46.28m |
| Inkomsten | -US$46.28m |
Laatst gerapporteerde inkomsten
Mar 31, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.20 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | -80.5% |
Hoe presteerde 2Q3A op de lange termijn?
Bekijk historische prestaties en vergelijking